IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.174,88 -1.842,71 (-3,18%)
ArriVent BioPharma, Inc. (AVBP)
Después del cierre:
ArriVent BioPharma, Inc.
18 Campus Boulevard
Suite 100
Newtown Square, PA 19073
United States
628-277-4836
https://www.arrivent.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 40
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Zhengbin Yao Ph.D. | Co-Founder, Chairman, President & CEO | 791,09k | N/A | 1966 |
| Dr. Stuart Lutzker M.D., Ph.D. | Co-Founder, President of Research & Development and Director | 709,43k | N/A | 1961 |
| Ms. Robin LaChapelle M.A. | Co-Founder & COO | 586,45k | N/A | 1973 |
| Mr. Winston Kung M.B.A. | CFO & Treasurer | N/A | N/A | 1976 |
| Ms. Yang Wang Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
| Mr. James Paul Kastenmayer J.D., Ph.D. | General Counsel & Secretary | N/A | N/A | 1972 |
| Dr. Dandan Dong | Chief Business Officer | N/A | N/A | 1985 |
| Ms. Meghna Chowdary | Senior Vice President of Commercial Strategy | N/A | N/A | N/A |
Descripción
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Gobierno corporativo
El ISS Governance QualityScore de ArriVent BioPharma, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
